Literature DB >> 15010360

Inflammation and Cancer II. Role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastrointestinal malignancy.

Mairi Macarthur1, Georgina L Hold, Emad M El-Omar.   

Abstract

It is well established that cancer arises in chronically inflamed tissue, and this is particularly notable in the gastrointestinal tract. Classic examples include Helicobacter pylori-associated gastric cancer, hepatocellular carcinoma, and inflammatory bowel disease-associated colorectal cancer. There is growing evidence to suggest that this association is not coincidental but may indeed be causal. In this review, we discuss the role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastrointestinal malignancy and outline some of the possible mechanisms involved.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15010360     DOI: 10.1152/ajpgi.00475.2003

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  117 in total

1.  Serologic evidence that ascaris and toxoplasma infections impact inflammatory responses to Helicobacter pylori in Colombians.

Authors:  Courtney Ek; Mark T Whary; Melanie Ihrig; Luis E Bravo; Pelayo Correa; James G Fox
Journal:  Helicobacter       Date:  2012-04       Impact factor: 5.753

2.  Therapeutic effect of orally administered microencapsulated oxaliplatin for colorectal cancer.

Authors:  Aleksandra M Urbanska; Emmanouil D Karagiannis; Gonzalo Guajardo; Robert S Langer; Daniel G Anderson
Journal:  Biomaterials       Date:  2012-04-01       Impact factor: 12.479

Review 3.  Mechanisms of intestinal inflammation and development of associated cancers: lessons learned from mouse models.

Authors:  Aya M Westbrook; Akos Szakmary; Robert H Schiestl
Journal:  Mutat Res       Date:  2010-03-16       Impact factor: 2.433

4.  Microbial Metabolites as Molecular Mediators of Host-Microbe Symbiosis in Colorectal Cancer.

Authors:  N P Hyland; A Houston; J M Keane; S A Joyce; C G M Gahan
Journal:  Results Probl Cell Differ       Date:  2020

5.  Pseudolaric acid B inhibits inducible cyclooxygenase-2 expression via downregulation of the NF-κB pathway in HT-29 cells.

Authors:  Li Hou; Bo Xu; Wei Guo; Fu-Xiang Ran; Jing-Tao Liu; Xia Yuan; Hong-Zheng Fu; Jing-Rong Cui
Journal:  J Cancer Res Clin Oncol       Date:  2012-05       Impact factor: 4.553

Review 6.  Anti-inflammatory/antioxidant use in long-term maintenance cancer therapy: a new therapeutic approach to disease progression and recurrence.

Authors:  Sarah Crawford
Journal:  Ther Adv Med Oncol       Date:  2014-03       Impact factor: 8.168

Review 7.  Inflammation and stem cells in gastrointestinal carcinogenesis.

Authors:  Michael Quante; Timothy Cragin Wang
Journal:  Physiology (Bethesda)       Date:  2008-12

8.  Genetic variation in the inflammation and innate immunity pathways and colorectal cancer risk.

Authors:  Hansong Wang; Darin Taverna; Daniel O Stram; Barbara K Fortini; Iona Cheng; Lynne R Wilkens; Terrilea Burnett; Karen W Makar; Noralane M Lindor; John L Hopper; Steve Gallinger; John A Baron; Robert Haile; Laurence N Kolonel; Brian E Henderson; Polly A Newcomb; Graham Casey; David Duggan; Cornelia M Ulrich; Loïc Le Marchand
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-09-17       Impact factor: 4.254

Review 9.  Polymorphism of IL-8 in 251 allele and gastric cancer susceptibility: a meta-analysis.

Authors:  Jing Wang; Hai-Feng Pan; Yun-Tao Hu; Yu Zhu; Qian He
Journal:  Dig Dis Sci       Date:  2009-09-24       Impact factor: 3.199

10.  Activation of NFkappaB represents the central event in the neoplastic progression associated with Barrett's esophagus: a possible link to the inflammation and overexpression of COX-2, PPARgamma and growth factors.

Authors:  Peter C Konturek; Agnieszka Nikiforuk; Joanna Kania; Martin Raithel; Eckhart Georg Hahn; Steffen Mühldorfer
Journal:  Dig Dis Sci       Date:  2004-08       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.